# CARGO Therapeutics

Source: https://onco.cc/companies/cargo-therapeutics/  
OnCo record `cargo-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CARGO developed a CAR T-cell therapy aimed at a protein called CD22 for patients with large B-cell lymphoma whose cancer had come back after CD19 CAR T treatment. It went public in 2023 and was bought by Concentra Biosciences in 2025 after winding down development.

## Summary

CARGO Therapeutics was a clinical-stage cell therapy company whose lead candidate, CRG-022, was an autologous CD22-directed chimeric antigen receptor (CAR) T-cell product for relapsed or refractory large B-cell lymphoma, including patients who had progressed after CD19 CAR T-cell therapy. The company began a potentially pivotal phase 2 trial (NCT05972720) in 2023 and completed a Nasdaq IPO raising about $281 million in November 2023. In July 2025 CARGO, by then describing itself as a company that had focused on CAR T-cell development, agreed to be acquired by Concentra Biosciences for $4.379 per share in cash plus a contingent value right tied to closing net cash above $217.5 million and to any disposition of remaining product candidates. The tender offer closed on 18 August 2025 and the merger completed the next day.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: San Carlos, CA
- Type: cell-therapy

## Notes

- Company website cargo-tx.com no longer resolves, so the SEC EDGAR company page is given as the website. Former Nasdaq ticker CRGX. Dateline was San Mateo in December 2023 and San Carlos in July 2025.

## Sources

- Official website: https://www.sec.gov/edgar/browse/?CIK=0001966494
- Concentra acquisition announcement (8-K, July 2025): https://www.sec.gov/Archives/edgar/data/1966494/000119312525156413/d74755dex991.htm
- Completion of acquisition (8-K, August 2025): https://www.sec.gov/Archives/edgar/data/1966494/000119312525183141/d58314d8k.htm
- Q3 2023 results describing CRG-022 (8-K): https://www.sec.gov/Archives/edgar/data/1966494/000119312523294468/d25647dex991.htm
- SEC EDGAR filings: https://www.sec.gov/edgar/browse/?CIK=0001966494

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/)

---
JSON: https://onco.cc/api/v1/entities/cargo-therapeutics.json